To assess the role of the IL-33/ST2 axis in glioma growth in vivo, we injected CT-2A glioma cells into the brains of ST2-deficient mice and monitored their tumor burden and survival outcome, compared to that of wild-type (wt) mice. Here, IL33 is linked to neoplasm.